22 October 2024
Mind Gym plc
("MindGym" or the "Company")
CFO succession and Board change
Further to the announcement of 28 August 2024 regarding its CFO succession plans, MindGym, the global provider of human capital and business improvement solutions, announces that Emily Fyffe has today been confirmed as Chief Financial Officer and appointed as a Director of the Company succeeding Dominic Neary.
Emily joined MindGym in 2016, has held increasingly senior finance roles in the Company and was announced as CFO Designate on 28 August 2024.
Emily holds 685 shares in the Company granted in October 2018 under the Share Incentive Plan and 423,700 options in the Company issued as part of Company's Long Term Investment Plan.
|
Mind Gym plc |
+44 (0) 20 7376 0626 |
|
Christoffer Ellehuus, Chief Executive Officer Emily Fyffe, Chief Financial Officer investors@themindgym.com
|
|
|
Panmure Liberum Limited (Nominated Adviser and Broker) |
+44 (0) 20 3100 2000 |
|
Nicholas How Anake Singh
|
|
|
MHP (for media enquiries) |
+44 (0) 7885 447 944 |
|
Reg Hoare Katie Hunt Veronica Farah |
|
About MindGym
MindGym is a company that delivers business improvement solutions using scalable, proprietary products which are based on behavioural science. The Group operates in three global markets: business transformation, human capital management and learning & development.
MindGym is listed on the London Stock Exchange Alternative Investment Market (ticker: MIND) and headquartered in London. The business has offices in London, New York and Singapore.
Further information is available at www.themindgym.com@themindgym
Regulatory Disclosures
Save for the information set out above, there are no further disclosures to be made in accordance with Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Emily Fyffe, aged 35.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
